Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of LNP1892 in Healthy Subjects
NCT02174237Phase 1Completed
- Sponsor
- Lupin Limited
- Start
- May 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing LNP1892 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single and multiple oral doses of LNP1892. Started May 2014; status: completed.
02
Drugs
LNP1892
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02174237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174237.